Annual report [Section 13 and 15(d), not S-K Item 405]

Cover Page

v3.25.0.1
Cover Page - USD ($)
 12 Months Ended
Nov. 30, 2024
Feb. 28, 2025
May 31, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Nov. 30, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Current Fiscal Year End Date --11-30    
Entity Interactive Data Current Yes    
Entity Current Reporting Status Yes    
Trading Symbol CCEL    
Entity Central Index Key 0000862692    
Entity Registrant Name CRYO-CELL INTERNATIONAL, INC.    
Entity Shell Company false    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity File Number 001-40767    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 22-3023093    
Entity Address, Address Line One 700 Brooker Creek Blvd    
Entity Address, Address Line Two Suite 1800    
Entity Address, City or Town Oldsmar    
Entity Address, State or Province FL    
Entity Address, Postal Zip Code 34677    
City Area Code 813    
Local Phone Number 749-2100    
Document Annual Report true    
Document Transition Report false    
Title of 12(b) Security Common Stock, $0.01 par value    
Entity Common Stock, Shares Outstanding   8,082,159  
Entity Public Float     $ 43,849,869
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Security Exchange Name NYSEAMER    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Documents Incorporated by Reference None    
Auditor Firm ID 344    
Auditor Name Wipfli LLP    
Auditor Location Atlanta, Georgia    
Auditor Opinion [Text Block]

We have audited the accompanying consolidated balance sheets of Cryo-Cell International, Inc. and subsidiaries (the “Company”), as of November 30, 2024 and 2023, and the related consolidated statements of operations, changes in stockholders’ deficit, and cash flows for the years then ended and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of November 30, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.